The Centers for Medicare & Medicaid Services today finalized additional provisions for the Medicare Advantage and Part D prescription drug programs beginning in 2022.

The rule permits a “preferred” specialty tier for Part D, which will provide a lower cost-sharing amount than the other specialty tier by allowing Part D plans more negotiating power with manufacturers.

The rule also codifies updates to Star Ratings for Part D plans and requires Part D plans to disclose pharmacy performance measures to CMS. Beginning in 2023, plans must provide a real-time benefit tool to help enrollees find the most cost-effective prescription drugs for their needs.

Related News Articles

Headline
The AHA today urged the Centers for Medicare & Medicaid Services to “take swift action to hold Medicare Advantage plans accountable for inappropriately and…
Headline
Last year, 42% of all Medicare beneficiaries received benefits through private Medicare Advantage plans, with enrollment in these plans growing by nearly 10%…
Headline
The Centers for Medicare & Medicaid Services Friday finalized policy and technical changes to the Medicare Advantage and prescription drug benefit for…
Headline
The Centers for Medicare & Medicaid Services should take steps to prevent Medicare Advantage organizations from denying coverage and payment for medically…
Headline
The Centers for Medicare & Medicaid Services yesterday finalized certain changes to Medicare Advantage maximum out-of-pocket and cost sharing limits for…
Headline
The Centers for Medicare & Medicaid Services yesterday announced final updates and changes to its Medicare Advantage and Part D payment methodologies for…